



ANAEMIA NEUTROPENIA THROMBOSIS AND CANCER COURSE

19th Annual Course

Vienna, Austria

March 27th - 28th, 2020

Chairs:

C. Bokemeyer, M. Dicato,
P. Gascon, H. Ludwig

Course co-ordinator:

M. Aapro

The course has been approved
to be announced as an
ESO Recommended Event



Auspices of:



EACCME accreditation has granted 6 European CME credits (ECMEC)

A course made possible thanks to the support of the Genolier Cancer Center.

Friday, March 27th, 2020

- 10:00 Registrations Open
- 12:00-13:00 Buffet Lunch
- 13:00-13:10 **Welcome:** Chairmen and Coordinator
- 13:10-15:10 **SESSION 1: Anaemia in Cancer Patients - Chairman: *M. Aapro***
 - 13:10-13:25 The ESMO and other guidelines including safety updates - *P. Gascon*
 - 13:30-13:50 Integrating iron management as per the ESMO guideline - *Y. Beguin*
 - 13:55-14:20 Transfusions: not a long-term alternative - *A. Hofmann*
 - 14:25-14:40 Discussion: applicability of the recommendations
- 14:45-15:10 **Break**
- 15:10-16:15 **SESSION 2: Biosimilars: not an issue in Europe anymore - Chairman: *M. Dicato***
 - 15:10-15:30 Biosimilars are just as good (by definition not better) as original drugs - *M. Dicato*
 - 15:35-15:55 A pharmacist's perspective - *R. Terkola*
- 16:00-16:15 General discussion
- 16:20-18:30 **SESSION 3: Platelets or Thrombosis - Chairman: *M. Dicato***
 - 16:20-16:35 Thrombocytopenia management, ITP included - *M. Dicato*
 - 16:40-17:00 New developments for thromboprophylaxis in cancer patients - *A. Young*
 - 17:10-17:40 DVT diagnosis and PE diagnosis in ambulatory cancer patients - *A. Falanga*
 - 17:50-18:10 Practical messages from 2019 International guideline: when to use what - *C. Ay*
- 18:10-18:30 General discussion

Faculty

Dr. Aapro Matti
 Prof. Ay Cihan
 Prof. Beguin Yves
 Prof. Bokemeyer Carsten
 Prof. Dicato Mario

Prof. Falanga Anna
 Dr. Gascon Pere
 Prof. Hofmann Axel
 Prof. Jordan Karin
 Prof. Link Hartmut

Prof. Ludwig Heinz
 Prof. Pettengell Ruth
 Prof. Santini Valeria
 Dr. Terkola Robert
 Prof. Young Annie

Saturday, March 28th, 2020

- 09:00-10:20** SESSION 4: Neutropenia in Cancer Patients: a session in collaboration with MASCC (requested). Chairman: *C. Bokemeyer*
- 09:00-09:15** Innovative not yet approved agents in neutropenia prevention - *M. Aapro*
- 09:20-09:40** A premiere about new ESMO guidelines on neutropenia management
ESMO/MASCC panel member - *M. Aapro*
- 09:45-10:00** Is there a case for long-acting G-CSF? - *H. Link*
- 10:05-10:20** ESMO and MASCC: resources in Supportive and Palliative Care - *K. Jordan*
- 10:30-11:00** Break
- 11:00-11:45** SESSION 5: The elderly cancer patient: a session in collaboration with SIOG
Chairman: *R. Pettengell*
- 11:00-11:20** Implications of anemia and neutropenia in the elderly patient - TBD
- 11:25-11:45** EPO and thrombopoietic agents in MDS - *V. Santini*
- 11:50-12:20** SESSION 6: Beyond solid tumours - Chairman: *H. Ludwig*
- 11:50-12:15** Role of EPOs and G-CSF in lymphoma (Hodgkin's and non-Hodgkin's) - *R. Pettengell*
- 12:20-12:35** LEARNING ASSESSMENT (LA) FOR CME
- 12:40...** CME certificates given only to those participants who have completed the LA
- 13:00-14:00** Buffet Lunch

CME information

EACCME accreditation has been requested.

Each participant will receive a certificate of attendance stating the relevant number of credits obtained during the conference

The CME certificates can be granted only to the participants who have attended the entire conference.

The CME certificates will be distributed only at the end of the meeting.

Topics covered during the course

- Supportive or palliative care: any difference?
- Consequences of anaemia
- Consequences of neutropenia with chemotherapy and other agents
- Treatment of anaemia and neutropenia in cancer patients, including older patients
- An understanding of biosimilars in oncology
- Prevention and treatment of thrombosis in cancer patients
- Evaluation of risk factors for anaemia or neutropenia or thrombosis
- Progress in thrombocytopenia management
- Transfusions: pros and cons
- Updated ESMO and other guidelines

Course Objectives

This course should clarify issues related to anaemia, neutropenia, thrombocytopenia and thrombosis in the cancer patient, including older patients, and the optimal way of preventing or treating these problems, including a review of guidelines. It will also focus on aspects still unresolved in the treatment of cancer treatment-associated anaemia like management of iron. All aspects will be discussed with participation from the audience, also using case studies.

At the end of the course the participants should be able to better prescribe preventative or corrective actions in these areas for cancer patients, including older patients, and critically follow the development of this important field in the near future.

Course venue

Lindner Hotel Am Belvedere
Rennweg 12 | A-1030 Wien

Organising secretariat

Visionplus Srl
Via Cortelona, 14 | 20900 Monza (MB) | Italy
Ph. +39 039 2326183 | Fax +39 039 3309918 | medicaleducation@visionplus.it

A course made possible thanks to



Financial support was provided by Pfizer Limited as a Medical and Educational Goods and Service.